Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors

Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the standard of care in advanced breast cancer. While Ki67 is prognostic in early-stage disease, including adjuvant CDK4/6i, its role in metastatic setting is unclear. This study assessed Ki67’s prognostic value in advanced bre...

Полное описание

Библиографические подробности

Главные авторы:	Marcin Kubeczko, Anna Polakiewicz-Gilowska, Katarzyna Świderska, Marta Mianowska-Malec, Aleksandra Leśniak, Barbarba Łanoszka, Konstanty Chomik, Barbara Grandys, Natalya Lisovska, Grzegorz Woźniak, Tomasz Latusek, Ewa Stobiecka, Jakub Simek, Bartłomiej Pyciński, Barbara Bobek-Billewicz, Ewa Chmielik, Michał Jarząb
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2026-02-01
Серии:	BMC Cancer
Предметы:	Advanced breast cancer Ki67 Ribociclib Abemaciclib Palbociclib
Online-ссылка:	https://doi.org/10.1186/s12885-026-15594-2
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!